What is the story about?
Shares of dialysis services provider Nephrocare Health Services, which operates under the NephroPlus brand, made their stock market debut on Wednesday, December 17.
The stock listed at a premium of 6.8% at ₹491.70 on the BSE. Similarly, on the NSE, the stock debuted at ₹490, a premium of 6.52%.
The company's ₹871.05 crore initial public offering was subscribed 13.96 times at the close of bidding, attracting bids worth nearly ₹8,600 crore from over 4.54 lakh applications.
The portion reserved for qualified institutional buyers was subscribed 27.47 times, while the non institutional investors segment saw demand of 24.27 times. The retail investors' quota was subscribed 2.31 times. The IPO was open for subscription from December 10 to December 12.
Nephrocare raised ₹353.4 crore through a fresh issue of shares, while promoters and existing investors offloaded up to 1.12 crore shares through an offer for sale.
Investcorp, Healthcare Parent, Edoras Investment Holdings, International Finance Corporation and 360 ONE were among the selling shareholders in the offer for sale.
Ahead of the public issue, the company had raised ₹260 crore from anchor investors at a price of ₹460 per share.
From the proceeds of the fresh issue, Nephrocare plans to invest ₹129.1 crore in setting up new dialysis clinics across India, allocate ₹136 crore towards repayment of borrowings, and use the remaining amount for general corporate purposes.
Nephrocare is India's largest dialysis services provider, with more than 50% share of the organised dialysis market. The company operates on a capital efficient and asset light model, with 52.4% of its clinics, as of September 2025, functioning under revenue sharing arrangements that require limited investment in physical infrastructure.
As of September 30, 2025, NephroPlus operated 519 clinics globally, including 51 centres in the Philippines, Uzbekistan and Nepal. In India, the company has the widest dialysis footprint, with clinics spread across 288 cities in 21 states and four union territories. Nearly 77% of its clinics are located in tier two and tier three cities.
On the financial front, Nephrocare's net profit nearly doubled to ₹67 crore in the financial year 2025 from ₹35.1 crore a year earlier, while revenue grew 33.5% to ₹755.8 crore from ₹566.2 crore. For the six months ended September 2025, the company reported a profit of ₹14.2 crore on revenue of ₹473.5 crore.
The stock listed at a premium of 6.8% at ₹491.70 on the BSE. Similarly, on the NSE, the stock debuted at ₹490, a premium of 6.52%.
The company's ₹871.05 crore initial public offering was subscribed 13.96 times at the close of bidding, attracting bids worth nearly ₹8,600 crore from over 4.54 lakh applications.
The portion reserved for qualified institutional buyers was subscribed 27.47 times, while the non institutional investors segment saw demand of 24.27 times. The retail investors' quota was subscribed 2.31 times. The IPO was open for subscription from December 10 to December 12.
Nephrocare raised ₹353.4 crore through a fresh issue of shares, while promoters and existing investors offloaded up to 1.12 crore shares through an offer for sale.
Investcorp, Healthcare Parent, Edoras Investment Holdings, International Finance Corporation and 360 ONE were among the selling shareholders in the offer for sale.
Ahead of the public issue, the company had raised ₹260 crore from anchor investors at a price of ₹460 per share.
From the proceeds of the fresh issue, Nephrocare plans to invest ₹129.1 crore in setting up new dialysis clinics across India, allocate ₹136 crore towards repayment of borrowings, and use the remaining amount for general corporate purposes.
Nephrocare is India's largest dialysis services provider, with more than 50% share of the organised dialysis market. The company operates on a capital efficient and asset light model, with 52.4% of its clinics, as of September 2025, functioning under revenue sharing arrangements that require limited investment in physical infrastructure.
As of September 30, 2025, NephroPlus operated 519 clinics globally, including 51 centres in the Philippines, Uzbekistan and Nepal. In India, the company has the widest dialysis footprint, with clinics spread across 288 cities in 21 states and four union territories. Nearly 77% of its clinics are located in tier two and tier three cities.
On the financial front, Nephrocare's net profit nearly doubled to ₹67 crore in the financial year 2025 from ₹35.1 crore a year earlier, while revenue grew 33.5% to ₹755.8 crore from ₹566.2 crore. For the six months ended September 2025, the company reported a profit of ₹14.2 crore on revenue of ₹473.5 crore.
